Skip to main content

Table 1 Study characteristics

From: Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials

Author Acronym Date Blinding Patient no. (tailored/control) Platelet function assay HPR cut-off
Aleil   2008 No 31/62 VASP VASP-PRI > 69%
Bonello   2008 No 78/84 VASP VASP-PRI > 50%
Bonello   2009 No 215/214 VASP VASP-PRI > 50%
Aradi DOSER 2010 Yes 36/38 LTA, 5 μM ADP >34%AGGmax
Price GRAVITAS 2010 No 1109/1105 VerifyNow,P2Y12 >230PRU
Ari EFFICIENT 2011 Yes 47/47 VerifyNow P2Y12 <40%inhibition
Hazarbasanov   2011 No 97/95 VerifyNow P2Y12 >208PRU
Tousek   2011 No 30/30 VerifyNow P2Y12 >240PRU
Trenk TRIGGER-PCI 2011 Yes 212/211 VerifyNow P2Y12 >208PRU
Wang   2011 No 150/156 VASP VASP-PRI > 50%
Collet ARCTIC 2012 No 1213/1227 VerifyNow,P2Y12 >235PRU
Samardzic   2014 No 43/44 MEA >46 U
Cayla ANTARCTIC 2016 No 435/442 VerifyNow,P2Y12 >208PRU
Author Clinical setting Modified treatment Intervention duration Follow-up
Aleil Scheduled for elective coronary stenting 150 mg MD clopidogrel 2 weeks 1 month
Bonello Stable angina:52% NSTEMI:48% STEMI: 0% Repeated 600 mg clopidogrel LD One week 30 days
Bonello Stable angina:48% NSTEMI:52% STEMI: 0% Repeated 600 mg clopidogrel LD One week 30 days
Aradi Stable angina:100% 600 mg LD +150 mg MD clopidogrel 1 month 12 months
Price Stable angina:60% NSTEMI:10.1% STEMI: 0.4% 600 mg LD +150 mg MD clopidogrel 6 months 6 months
Ari Stable angina:100% 150 mg MD clopidogrel 1 month 6 months
Hazarbasanov Stable angina:43% NSTEMI:33% STEMI: 24% 600 mg LD +150 mg clopidogrel 1 month 6 months
Tousek Stable angina:23% NSTEMI:34% STEMI: 43% clopidogrel starting at 150 mg/day with further dose increase 1 month 6 months
Trenk Stable angina:100% 60 mg LD +10 mg MD Prasugrel 6 months 6 months
Wang Stable angina:80% NSTEMI:20% STEMI: 0% increase in clopidogrel MD up to 375 mg 11 months 1 year
Collet Scheduled for elective coronary stenting Repeated 600 mg clopidogrel LD + 150 mg MD clopidogrel/10 mg MD Prasugrel 12 months 12 months
Samardzic Stable angina:16% NSTEMI:23%STEMI:60% up to clopidogrel 600 mg × 2 + (75-300 mg MD) 12 months 12 months
Cayla Stable angina:18% NSTEMI:48%STEMI:34% 5–10 mg MD Prasugrel 12 months 12 months
  1. Abbreviations ACS acute coronary syndrome, CV cardiovascular, HTPR high on-treatment platelet reactivity, LD loading dose, MD maintenance dose, MI myocardial infarction, STEMI ST-segment elevation myocardial infarction, NSTEMI non-ST segment elevation myocardial infarction, ST stent thrombosis, TVR target vessel revascularization, MACE major adverse cardiovascular events RCT randomized, controlled trial